New York State Common Retirement Fund raised its stake in shares of AnaptysBio Inc (NASDAQ:ANAB) by 21.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,500 shares of the biotechnology company’s stock after acquiring an additional 1,500 shares during the period. New York State Common Retirement Fund’s holdings in AnaptysBio were worth $297,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANAB. Artal Group S.A. boosted its position in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after acquiring an additional 205,310 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new position in shares of AnaptysBio during the 3rd quarter valued at approximately $1,922,000. Northern Trust Corp boosted its position in shares of AnaptysBio by 360.6% during the 2nd quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock valued at $1,436,000 after acquiring an additional 47,005 shares during the last quarter. State Street Corp boosted its position in shares of AnaptysBio by 108.8% during the 2nd quarter. State Street Corp now owns 74,833 shares of the biotechnology company’s stock valued at $1,791,000 after acquiring an additional 38,996 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of AnaptysBio by 22.6% during the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after acquiring an additional 37,932 shares during the last quarter. 75.48% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on ANAB. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, September 13th. Jefferies Group began coverage on AnaptysBio in a research report on Thursday, November 9th. They set a “buy” rating and a $101.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $75.00 target price (up from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a research report on Tuesday, September 12th. Finally, Royal Bank of Canada began coverage on AnaptysBio in a research report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $88.00.

Shares of AnaptysBio Inc (NASDAQ ANAB) opened at $101.48 on Monday. AnaptysBio Inc has a 52-week low of $15.17 and a 52-week high of $104.87. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. equities analysts anticipate that AnaptysBio Inc will post -1.72 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AnaptysBio Inc (ANAB) Shares Bought by New York State Common Retirement Fund” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/anaptysbio-inc-anab-shares-bought-by-new-york-state-common-retirement-fund/1798363.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with Analyst Ratings Network's FREE daily email newsletter.